Table 2.
Proven strategies to overcome NK cytotoxicity against pig endothelial cells.
| Target | Approach | NK source | Effect | Reduction (%) | Ref |
|---|---|---|---|---|---|
| αGal GT | In vitro knockout pEC lines | IL2-NK cells, NK92 Fresh NK cells, Fresh NK cells |
No effect CMC ↓ ADCC ↓ nAb/CML |
NA 77–90 86 |
[46, 126] |
| Gal knockout pigs | IL2-NK cells, Fresh NK cells Fresh NK cells |
No effect in CMC ↓ ADCC ↓ nAb/CML |
NA 70 80 |
[47, 124] | |
| siRNA in pEC | NK92 cell line | No effect CMC ↓ ADCC |
NA 30–40 |
[125] | |
|
| |||||
| Masking of sugar xenoantigens | Transfections of α(1,2)-fucosyltransferase in pECs | Fresh NK cells | ↓ CMC | 47 | [119] |
| Treatment of pECs with DXS | NK92 | ↓ CMC inh. C' deposition |
25–47 | [135] | |
|
| |||||
| HLA class I molecules | HLA-E transfection in pEC | IL2-NK cells | ↓ CMC | 15–60 | [150, 151] |
| HLA-E transgenic pigs | IL2-NK cells | ↓ CMC ↓ IFNγ production |
8–30 40 |
[15] | |
| HLA-G1 transfection in pEC | IL2-NK cells, NK92 and NK cell clones | ↓ CMC ↓ rolling/adhesion No effect in ADCC |
20–45 25–75 NA |
[141, 142, 150, 187] | |
| Soluble HLA-G1 | NK92 Fresh PBMC |
↓ CMC ↓ CMC |
31–83 24 |
[145] | |
| HLA-Cw3 transfection in pEC | NK cell clones | ↓ CMC | 12–70 | [136] | |
| HLA-Cw4 transfection in pEC | NK cell clones | ↓ CMC | 58 | [139] | |
| HLA-B27 transfection in pEC | NK cell clones | ↓ CMC | ~30 | [136] | |
|
| |||||
| Apoptosis induction | PK15, human FasL transfection | PBL | ↓ ADCC | 34–42 | [108] |
| PK15, human FasL transfection | PBL, LAK |
↓ ADCC ↓ CMC |
54 74 |
[127] | |
| pEC, human FasL transfection | IL2-NK cells | No effect CMC ↑ apoptosis NK cells |
0 | [129] | |
| pEC, pig FasL transfection | IL2-NK cells | ↓ CMC ↓ FasL apoptosis |
26 23 |
[128] | |
|
| |||||
| Apoptosis resistance | Bcl-2 transfection in PK15 | PBL | ↓ FasL apoptosis ↓ ADCC |
62 50 |
[132] |
| Bcl-2mut transfections in pEC | IL2-NK cells | No effect CMC | 0 | [110] | |
ADCC: antibody-dependent cell-mediated cytotoxicity; αGal GT: alpha1,3-galactosyltransferase; C': complement; CML: complement-mediated lysis, CMC: cell-mediated cytotoxicity; DXS: dextran sulfate; HLA: human leukocyte antigen; IFNγ: interferon gamma; inh.: inhibition; LAK: lymphokine-activated killer; NA: not applicable; nAb: natural antibody; PBL: peripheral blood lymphocytes; PBMC: peripheral blood mononuclear cells; pEC: porcine endothelial cells; PK15: pig kidney cell line; siRNA: short interfering RNA; ↓: reduction.